Zuranolone (Zurzuvae): The New Pill for Postpartum Depression

For decades, treating postpartum depression meant the same tools used for any depression: talk therapy and antidepressants that take weeks to work. In 2023, that changed. Zuranolone, sold as Zurzuvae, became the first pill the FDA approved specifically for postpartum depression, and it works in a genuinely different way.

Zuranolone is a 14-day course of daily pills, taken at home, that tends to work fast, often within a few days rather than the weeks a standard antidepressant needs. It isn't right for everyone, but for moderate-to-severe postpartum depression it's a meaningful new option.

What makes it different

Two things set zuranolone apart. The first is the timeline: it's a short, defined course of two weeks, not a medication you take indefinitely, and relief often begins within days. The second is how it works. Zuranolone is a neuroactive steroid that acts on GABA-A receptors, the brain's main calming system, by mimicking allopregnanolone, a soothing byproduct of progesterone that drops sharply after birth. That post-delivery drop is part of the biology behind postpartum depression, and zuranolone is designed to address it directly.

How it compares to the older option

Zuranolone isn't the first medication aimed at this. Brexanolone, approved in 2019, was the first, and it works on the same system, but it required a 60-hour intravenous infusion in a hospital, which made it hard to access; it has since been withdrawn from the US market. Zuranolone delivers a related approach as a pill you take at home, which is a large step forward for accessibility (ACOG; eBioMedicine, 2023).

What it's like to take

Zuranolone is taken once daily in the evening, with food, for 14 days. The most common effect is drowsiness, which is why you shouldn't drive or operate machinery for at least 12 hours after each dose. It's a controlled substance, and other side effects can include dizziness and fatigue. In the trials behind its approval, women with severe postpartum depression improved significantly faster than those on placebo, with a difference showing as early as the third day (eBioMedicine, 2023).

Where it fits in treatment

Zuranolone doesn't replace the mainstays. Therapy and SSRIs remain central to treating postpartum depression, and SSRIs, though they take longer to work, are taken over a longer period and have a deep track record. Major guidance suggests considering zuranolone for moderate-to-severe depression that begins late in pregnancy or within about four weeks of birth (ACOG). For some, it's used alongside an ongoing antidepressant. Cost and access can be real barriers, and that's worth discussing openly with a clinician. If you want a sense of how the standard antidepressant route feels by comparison, our piece on how long an SSRI takes to work lays out that timeline.

What about breastfeeding?

This is an honest gap. Data on zuranolone during breastfeeding are still limited, so the decision calls for an individual conversation with your clinician, weighing the benefits against the uncertainty. For many parents who are nursing, a well-studied SSRI remains the more established choice; our guide to antidepressants while breastfeeding covers those options.

The bottom line

Zuranolone is a real advance: a fast-acting, two-week oral treatment built specifically for postpartum depression, and one that can reach people with moderate-to-severe symptoms sooner than a standard antidepressant. Whether it fits you depends on your symptoms, their timing, whether you're breastfeeding, and access. A clinician can help you weigh it against the other effective options.

If you're struggling, or having any thoughts of harming yourself or your baby, please don't wait. Call or text 988, the Suicide & Crisis Lifeline, any time.

Book your first evaluation to talk through whether zuranolone or another approach fits your situation.

If any of this sounds familiar, you don't have to sort it out alone - book your first evaluation and we'll take it from there.